Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
INM 
InMed Pharmaceuticals Inc (INM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: INM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -59.77% | Avg. Invested days 13 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.08M USD | Price to earnings Ratio - | 1Y Target Price 20 |
Price to earnings Ratio - | 1Y Target Price 20 | ||
Volume (30-day avg) - | Beta 0.28 | 52 Weeks Range 1.72 - 9.38 | Updated Date 06/29/2025 |
52 Weeks Range 1.72 - 9.38 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -11.65 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -168.9% | Operating Margin (TTM) -167.67% |
Management Effectiveness
Return on Assets (TTM) -44.64% | Return on Equity (TTM) -91.71% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 297344 | Price to Sales(TTM) 0.83 |
Enterprise Value 297344 | Price to Sales(TTM) 0.83 | ||
Enterprise Value to Revenue 0.06 | Enterprise Value to EBITDA 1 | Shares Outstanding 1207190 | Shares Floating 1205387 |
Shares Outstanding 1207190 | Shares Floating 1205387 | ||
Percent Insiders 1.45 | Percent Institutions 10.18 |
Upturn AI SWOT
InMed Pharmaceuticals Inc
Company Overview
History and Background
InMed Pharmaceuticals Inc. is a biopharmaceutical company specializing in the research, development, and commercialization of cannabinoid-based therapies. Founded in 2014, they focus on developing novel therapeutics for diseases with high unmet medical needs.
Core Business Areas
- Drug Development: Developing novel cannabinoid-based drug candidates for the treatment of various diseases including dermatological and ocular indications.
- CBN Manufacturing: Focusing on developing and scaling up proprietary manufacturing processes to produce pharmaceutical-grade cannabinol (CBN).
Leadership and Structure
The leadership team consists of management with experience in pharmaceutical development and commercialization. Organizational structure is typical of a biotech company, with distinct research, development, and administrative departments.
Top Products and Market Share
Key Offerings
- INM-755 (CBDV topical cream): A topical cannabidiol valerate (CBDV) cream being developed for the treatment of epidermolysis bullosa (EB). No current market share data. Competitors include companies developing gene therapies and other treatments for EB. Limited market share data available, focus on orphan drug designation advantages. The market is highly fragmented, with no single dominant player. The market consists of specialized therapeutics, wound care products, and pain management solutions. Market Size ~$800M.
- INM-901: A systemic cannabinoid being developed for ocular indications. No current market share data. Competitors include companies developing therapies for glaucoma and other eye diseases. Competitors include pharmaceutical giants like Allergan (ABBV) and Novartis (NVS), which offer established glaucoma treatments. Market size ~ 6B.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and regulated, with significant opportunities in developing novel therapies for unmet medical needs. The cannabinoid therapeutics sector is emerging and rapidly evolving.
Positioning
InMed is positioned as a specialty biopharmaceutical company focused on developing cannabinoid-based therapies. Their competitive advantage lies in their proprietary drug development platform and focus on specific disease areas.
Total Addressable Market (TAM)
The total addressable market for InMed's pipeline products is estimated to be in the billions of dollars, focusing on unmet needs such as EB and glaucoma. Their positioning within this TAM is dependent on successful clinical trials and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Proprietary drug development platform
- Focus on cannabinoid-based therapies
- Pipeline of novel drug candidates
- Orphan drug designation potential
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- Regulatory uncertainty surrounding cannabinoids
- Early stage development
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline into new indications
- Successful clinical trials and regulatory approvals
- Growing acceptance of cannabinoid-based therapies
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Negative perception of cannabinoids
Competitors and Market Share
Key Competitors
- ABBV
- NVS
- VYNE
- ZTS
Competitive Landscape
InMed faces strong competition from established pharmaceutical companies with greater financial and research resources. However, its focus on cannabinoid-based therapies provides a niche advantage in certain indications.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited as InMed is still in the development stage.
Future Projections: Future growth is dependent on the successful development and commercialization of its pipeline products.
Recent Initiatives: Recent initiatives include advancing INM-755 into clinical trials and continuing development of INM-901.
Summary
InMed Pharmaceuticals is a development-stage biopharmaceutical company focused on cannabinoid-based therapies. Its success hinges on the progression of its drug candidates through clinical trials and regulatory approval, which is inherently risky. The company's strengths lie in its proprietary platform, but its weaknesses include limited resources and dependence on clinical success. Overall, InMed's future depends on strategic partnerships and successful execution of its development plans.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Market Research Reports
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About InMed Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Vancouver, BC, Canada | ||
IPO Launch date 2020-11-12 | President, CEO & Director Mr. Eric A. Adams B.S. Chem., M.I.B. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 13 | Website https://www.inmedpharma.com |
Full time employees 13 | Website https://www.inmedpharma.com | ||
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. It operates through two segments: InMed Pharma and BayMedica Commercial. The InMed Pharma segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-089, which is a small molecule compound acting as a selective dual CB1 /CB2 agonist; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.